Dreman Value Management L L C held its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,646 shares of the company’s stock at the end of the second quarter. Dreman Value Management L L C’s holdings in Teva Pharmaceutical Industries Limited were worth $502,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. San Francisco Sentry Investment Group CA purchased a new position in shares of Teva Pharmaceutical Industries Limited in the second quarter worth about $106,000. Kistler Tiffany Companies LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares in the last quarter. FNY Managed Accounts LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited in the first quarter worth about $123,000. Finally, Sterling Investment Advisors Ltd. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 56.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Position Maintained by Dreman Value Management L L C” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/16/teva-pharmaceutical-industries-limited-teva-position-maintained-by-dreman-value-management-l-l-c.html.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 0.13% during midday trading on Monday, hitting $14.96. 7,189,280 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a 52-week low of $14.30 and a 52-week high of $44.42. The firm’s 50-day moving average is $16.73 and its 200 day moving average is $26.05. The firm’s market cap is $15.20 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same period last year, the business posted $1.25 earnings per share. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.24 earnings per share for the current year.

TEVA has been the subject of several recent research reports. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 target price for the company in a research note on Wednesday, June 28th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $37.00 target price (down previously from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, July 17th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $21.00 target price (down previously from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, August 31st. Finally, BTIG Research upgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Monday, September 11th. Five investment analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $27.63.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.